Presents Phase 1/2 Clinical Data on Casdozokitug, a First in Class IL 27 Targeted Antibody, at the 2023 ESMO Immuno Oncology Congress

Press/Media

Period6 Dec 2023

Media coverage

1

Media coverage

  • TitlePresents Phase 1/2 Clinical Data on Casdozokitug, a First in Class IL 27 Targeted Antibody, at the 2023 ESMO Immuno Oncology Congress
    Media name/outletMarket News Publishing
    Country/TerritoryUnited States
    Date6/12/23
    PersonsThomas Marron
View all 1
View less